Drug Trial Radar · NCT01223534
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
Last checked: Nov 19, 2026Latest source record: May 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
871
Actual
Start
Jul 2010
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- Hospital Universitari de BellvitgeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cellestis
- First posted
- Oct 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypothesis: a combined strategy of tuberculin skin test (TST) followed by QuantiFERON-TB Gold In-Tube (QFT-IT) to confirm positivity (tuberculosis infection,in contact-tracing study will allow avoiding unnecessary preventive treatment without increasing rates of tuberculosis cases among contacts screened. Aim of the study: to compare a combined strategy of the TST and the QFT-IT with TST alone for the diagnosis of tuberculosis infection and for therapeutic decision in contact tracing study. Design and setting: Prospective, multicentre, comparative study in 12 hospitals in Spain. Study population: 870 subjects, household contacts of patients with culture positive pulmonary and/or laryngeal tuberculosis will be randomized to one of two strategies: Arm A (standard practice), in which treatment decisions will be based on the TST result, and Arm B (experimental), in which treatment decisions will be based on the QFT result. Interventions: participants in arm A will undergo TST; participants in arm B will undergo TST, and, in case of a positive result, QFT-IT as well. Participants with positive TST (arm A) and positive QFT-IT (arm B) will be diagnosed with tuberculosis infection and will be treated with isoniazid for 6 months. All participants will be followed for two years. End-points of evaluation: development of tuberculosis and proportion of subjects for whom treatment is prescribed in each arm.
Conditions
- Latent Tuberculosis Infection
Interventions
Preventive treatment with Isoniazid.Drug
If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
Preventive treatment with IsoniazidDrug
If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of tuberculosis.Time frame: Assessment of primary end-point: 24 months after randomization.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bellvitge University Hospital, IDIBELL
L'Hospitalet de Llobregat, Barcelona, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.